Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study - Miyamoto, Kyoko; Miller, Robert M.; Voors‐Pette, Christine; Oosterhaven, Jart A. F.; Dobbelsteen, Marieke; Mihara, Katsuhiro; Geldof, Marian; Sato, Yuji; Matsuda, Naomi; Kirita, Shirou; Sawa, Masaaki; Arimura, Akinori (Clinical and translational science, 2024)
Keywords: Administration, Oral; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors; Allergies; Arthritis; Autoimmune diseases; Biochemistry; Bruton's tyrosine kinase; Cell activation; Cytokines; Dosage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug dosages; Electrocardiography; Female; Females; Half-Life; Healthy Volunteers; Hematology; Humans; Investigations; Kinases; Leukocytes (basophilic); Male; Middle Aged; Pharmacodynamics; Pharmacokinetics; Plasma; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - pharmacology; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; Pyrimidines - pharmacology; Therapeutic targets; Urinalysis; Young Adult; Netherlands